6th Microbiome Movement - Drug Development Summit Europe

As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.

The 6th Microbiome Movement – Drug Development Summit Europe will return online to unite leading scientists and industry partners surrounding the microbiome to pursue the causal role of the microbiome in disease, with the aim to obtain the first EMA-approved microbiome-targeted therapeutic from predictable modes of action and consistent clinical outcomes. Join us to explore the progress made in the last 12 months, and uncover where this microbiome space is heading!

Group discounts and early booking rates are available. Please visit the website for full pricing information.

Speakers: Charles Bundinof, Strain Discovery and Microbiome Science Lead, IFF, Denise Kelly, Investment Advisor, Seventure, Duncan Peyton, CEO, 4D Pharma PLC, Hervé Affagard, CEO, MaaT Pharma, John Hambor, Director, Research Beyond Borders, Boehringer Ingleheim, Kristin Wannerberger, Director R&D Alliance Management, Ferring, Mike Ramonas, CEO, Microbiotica, Yogesh Mudaliar, Global Millennial Advisory Board Member CEO, Takeda, Sonia Timberlake, Senior Vice President, Finch, Shiri Meshner, VP R&D, Biomica LtD, Tomas de Wouters, Co-founder and CEO, PharmaBiome, Barbara McGovern, M. D. VP Medical Affairs, Seres Therapeutics, Celine Druart, Pharmabiotic Research Institute, Microbiome Project Manager, Paul Carlson, Principal Investigator, FDA, Anders Damholt, Head of Clinical Development, Chr. Hansen, Adam Wilkinson, Pre-Clinical Development, Microbiotica

Others Details

Brochure: https://go.evvnt.com/919896-3?pid=6581